first glp 1 drug Evolution of GLP‐1 Receptor Agonists for Diabetes Treatment FDA Approves First ORAL GLP-1
Description
Vallof et al., 2020)

Guevara, L

Hsu CY, McCulloch CE, Iribarren C et al

doi: 10.1152/ajpendo.1982.242.3.E206 87 ZieglerRBellwinkelSSchmidtchenDMinneH

For the side effect models, we focused on the two phenotypes for which GWAS SNPs were identified (Supplementary Table 21)

Vishal Manchanda, equity research analyst-pharma, Systemix Group, explains the significance: "The advantage with non-peptide is that they can be quickly scaled up and cost less to produce." Swapnil Shah, MD of Senores Pharma, adds a cautionoral GLP-1s are not standard small molecules
